## **Amendments to the Claims**

## 1. (Currently Amended) A compound of the formula:

Formula I

wherein,

X represents -CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>O , -CH<sub>2</sub>S , or -CH<sub>2</sub>NR<sup>10</sup>- or -CH<sub>2</sub>O-;

 $R^1$  represents hydrogen,  $(C_1-C_4)$ alkyl,  $(C_3-C_7)$ cycloalkyl, hydroxy $(C_1-C_4)$ alkyl, halo $(C_1-C_4)$ alkyl,  $(C_1-C_4)$ alkyl-heterocycle,  $(C_1-C_4)$ alkyl-NH $(C_1-C_4)$ alkylamine, or  $(C_1-C_4)$ alkyl-N,N- $(C_1-C_4)$ dialkylamine;

R<sup>2</sup> represents hydrogen, halo, (C<sub>1</sub>-C<sub>4</sub>)alkyl, heterocycle, or substituted heterocycle;

R<sup>3</sup> represents hydrogen, halo, (C<sub>1</sub>-C<sub>4</sub>)alkyl, heterocycle, or substituted heterocycle;

R<sup>4</sup> represents NHSO<sub>2</sub>CH<sub>3</sub>;

R<sup>5</sup> represents hydrogen;

 $R^6$  represents hydrogen or  $(C_1-C_4)$ alkyl;

 $R^7 \ represents \ (C_1-C_4) alkyl, \ aryl, \ NH(C_1-C_4) alkylamine, \ or \ N, N-(C_1-C_4) dialkylamine;$ 

 $R^8$  represents  $(C_1-C_4)$ alkyl,  $(C_1-C_4)$ alkoxy, or  $aryl(C_1-C_4)$ alkoxy;

 $R^9$  represents (C<sub>1</sub>-C<sub>4</sub>)alkyl or (C<sub>1</sub>-C<sub>4</sub>)alkoxy, and

 $R^{10}$  represents hydrogen, (C1-C4)alkyl, (C3-C7)cycloalkyl, or (C1-C4)alkyl-(C3-C7)cycloalkyl,

or a pharmaceutically acceptable salt thereof.

- 2. (Cancelled)
- 3. (Cancelled)

- 4. (Currently Amended) The compound according to Claim 3 Claim 1 wherein X represents -CH<sub>2</sub>- or -CH<sub>2</sub>CH<sub>2</sub>-.
- 5. (Currently Amended) The compound according to Claim 3 Claim 1 wherein X represents -CH<sub>2</sub>O-.
  - 6. (Cancelled)
- 7. (Previously Presented) The compound according to Claim 1 wherein  $R^1$  represents hydrogen, methyl, ethyl, propyl, isopropyl,  $(C_3-C_7)$ cycloalkyl, hydroxy $(C_1-C_4)$ alkyl, halo $(C_1-C_4)$ alkyl,  $(C_1-C_4)$ alkyl-heterocycle,  $(C_1-C_4)$ alkyl-NH $(C_1-C_4)$ alkylamine, or  $(C_1-C_4)$ alkyl-N,N- $(C_1-C_4)$ dialkylamine.
- 8. (Original) The compound according to Claim 7 wherein  $R^1$  represents methyl, ethyl, propyl, isopropyl,  $(C_3-C_7)$ cycloalkyl, hydroxy $(C_1-C_4)$ alkyl, halo $(C_1-C_4)$ alkyl,  $(C_1-C_4)$ alkyl-heterocycle,  $(C_1-C_4)$ alkyl-NH $(C_1-C_4)$ alkylamine, or  $(C_1-C_4)$ alkyl-N,N- $(C_1-C_4)$ dialkylamine.
- 9. (Previously Presented) The compound according to Claim 1 wherein R<sup>2</sup> represents hydrogen, halo, methyl, ethyl, propyl, isopropyl, heterocycle, or substituted heterocycle.
- 10. (Original) The compound according to Claim 9 wherein R<sup>2</sup> represents hydrogen, fluoro, chloro, bromo, methyl, ethyl, propyl, or isopropyl.
- 11. (Previously Presented) The compound according to Claim 1 wherein R<sup>3</sup> represents hydrogen, fluoro, chloro, or bromo.
- 12. (Original) The compound according to Claim 11 wherein R<sup>3</sup> represents hydrogen or fluoro.
  - 13. (Cancelled)
  - 14. (Cancelled)
  - 15. (Cancelled)
  - 16. (Cancelled)
  - 17. (Cancelled)
- 18. (Previously Presented) The compound according to Claim 1 wherein R<sup>6</sup> represents hydrogen, methyl, or ethyl.
- 19. (Previously Presented) A pharmaceutical composition comprising the compound according to Claim 1 in combination with a pharmaceutically acceptable carrier, diluent, or excipient.

- 20. (Cancelled)
- 21. (Cancelled)
- 22. (Cancelled)
- 23. (Cancelled)
- 24. (Cancelled)
- 25. (Cancelled)
- 26. (Cancelled)
- 27. (Cancelled)
- 28. (Cancelled)
- 29. (Cancelled)
- 30. (Cancelled)
- 31. (Cancelled)
- 32. (Cancelled)
- 33. (Cancelled)
- 34. (Previously Presented) A compound selected from the group consisting of N-[3-(1-Ethyl-5-fluoro-indan-1-yl)-1H-indol-7-yl]-methanesulfonamide, N-[3-(6-Fluoro-1-methyl-1,2,3,4-tetrahydro-naphthalen-1-yl)-1H-indol-7-yl]-methanesulfonamide, N-[3-(6,8-Difluoro-1-methyl-1,2,3,4-tetrahydro-naphthalen-1-yl)-1H-indol-7-yl]-methanesulfonamide, N-[3-(4-Ethyl-7-fluoro-chroman-4-yl)-1H-indol-7-yl]-methanesulfonamide, and N-[3-(1-Cyclopropyl-5-fluoro-indan-1-yl)-1H-indol-7-yl]-methanesulfonamide, a pharmaceutically acceptable salt thereof.